

**WEDNESDAY 15<sup>th</sup> JANUARY 2014 COMMENCING 10.30 AM**

**(UNTIL 4.00 PM APPROX)**

**AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN**

**AGENDA**

**Enclosure**

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0114

***To protect commercial confidentiality, the first appraisal will be conducted in private.  
The final appraisal recommendation will be announced in public***

5. **Appraisal 1 – Full submission (WPAS)**  
**Abatacept (Orencia®)** in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor

2/AWMSG/0114  
**Appendices**

***The meeting will now open to the public (approx 11.15 am)***

6. **Chairman's report (verbal update)**
7. **AWMSG Medicines Strategy for Wales**
8. **Appraisal 2 – Full submission**  
**Atomoxetine (Strattera®)** for the initiation of treatment in adults with attention deficit hyperactivity disorder (ADHD)
9. **AWMSG National Prescribing Indicators 2014-15**
10. **Appraisal 3 – Full submission**  
**Linacotide (Constella®)** for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults

3/AWMSG/0114

4/AWMSG/0114  
**Appendices**

5/AWMSG/0114

6/AWMSG/0114  
**Appendices**

- |   |                                   |
|---|-----------------------------------|
| 11. <b>Appraisal 4 – Full submission</b><br><b>Nalmefene (Selincro®)</b> for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment | 7/AWMSG/0114<br><b>Appendices</b> |
| 12. <b>AWPAG update (draft minutes of December 2013 meeting)</b>  | 8/AWMSG/0114                      |
| 13. <b>CEPP/Therapeutics Priorities 2014</b>  | 9/AWMSG/0114                      |
| 14. <b>Date of next meeting:</b><br><b>Wednesday 19<sup>th</sup> February in Abergavenny</b>  |                                   |